Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

182 $(1,591) $ 1,057

Diluted earnings

per common share:

(Loss)/earnings

available to

common shareholders

before cumulative

effect of a change

in accounting

principle $(2.08) $0.12 $(1.04) $0.69

Cumulative effect

of a change in

accounting

principle,

net of tax 7/ - - - 0.02

Diluted (loss)/

earnings per

common share $(2.08) $0.12 $(1.04) $0.71

Average common

shares outstanding

- diluted 1,621 1,497 1,536 1,491

The company incurs substantial costs related to the cholesterol joint venture, such as selling, general and administrative costs, that are not reflected in the "Equity income" and are borne by the overall cost structure of Schering-Plough.

1/ Net sales for the three and twelve months ended December 31, 2007,

both include $626 million of Organon BioSciences (OBS) net sales for

the period November 19, 2007 to December 31, 2007.

2/ Cost of sales for the three and twelve months ended December 31, 2007

both include purchase accounting adjustments of $326 million related

to the acquisition of OBS. Cost of sales for the three and twelve

months ended December 31, 2006 include $45 million and $146 million,

respectively, related to the manufacturing changes announced June 1,

2006.

3/ Research and development for the three and twelve months ended

December 31, 2007 include $21 million and $197 million related to

upfront R&D payments. Research and development for the three and

twelve months ended December 31, 2006 both include $15 million related

to an upfront R&D payment.

4/ Acquired in-process research and development for the three a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... equities: Genetic Technologies Ltd (NASDAQ: GENE ), ... Fisher Scientific Inc. (NYSE: TMO ), Sequenom ... (NYSE: PKI ). Free research report on ... . On Thursday, April 30, 2015, the NASDAQ ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
(Date:4/30/2015)... Spirax Sarco, the leader in product ... announce that for the first time in the company’s ... a Queen’s Award for Innovation – the UK’s highest ... of a unique flowmeter. , The Spirax Sarco ... steam flow measurement. The device provides reliable, accurate ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Immunotech Laboratories (Pink Sheets: IMMB) is happy ... potential venture for South America, headquartered in Mexico. ... Laboratories, the potential outcome from these discussions, will ... and position the company for a viable regional ...
... FRANCISCO, April 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... letter, dated March 31, 2009, from the staff of ... does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). ...
... to leverage technologies for PACS data disaster recoveryCHICAGO, April ... business unit of Siemens Healthcare ( ... Corporation ( www.harris.com ... solutions critical for Picture Archiving and Communication Systems (PACS) ...
Cached Biology Technology:Immunotech Laboratories Announces South American Strategy 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4Siemens Healthcare Announces Planned Collaboration with Harris Corporation 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 3Siemens Healthcare Announces Planned Collaboration with Harris Corporation 4
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... potential for preventing cardiomyopathy, a form of heart disease that ... scientists have concluded in a new study. Their report, which ... for diabetic cardiomyopathy, appears in ACS, bi-weekly Journal of ... note that people with diabetes have at least twice the ...
... of up to 4.2 C and the end of ... are not revised in the Copenhagen Accord, the international pledge ... conference. Just ahead of the next United ... Tianjin, China, a new report published today, Wednesday, 29 September, ...
... 2010) "Migraine feels like God just punched you in ... his interview on the American Migraine Foundation,s (AMF) new podcast ... crisis." In the interview AMF,s president Barry Baumel MD, ... pain of migraine, how not to be a "nave" patient, ...
Cached Biology News:Climate accord loopholes could spell 4.2-degree rise in temperature and end of coral reefs by 2100 2American Migraine Foundation launches new podcast series 2
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Silica bead method is an economic method of DNA extraction from agarose...
...
...
Biology Products: